低至中危1型骨髓增生异常综合征输血依赖患者的铁螯合治疗 - Suppr | 超能文献

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes.

作者信息

Lucijanic Marko, Lovrinov Miran, Skelin Marko

机构信息

University Hospital Dubrava, Zagreb, Croatia (M.L.).

MakPharm, Zagreb, Croatia (M.L.).

出版信息

Ann Intern Med. 2020 Oct 6;173(7):595. doi: 10.7326/L20-1055.

DOI:10.7326/L20-1055

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes.低至中危1型骨髓增生异常综合征输血依赖患者的铁螯合治疗

Ann Intern Med. 2020 Oct 6;173(7):595. doi: 10.7326/L20-1055.

2

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes.低至中危1型骨髓增生异常综合征输血依赖患者的铁螯合治疗

Ann Intern Med. 2020 Oct 6;173(7):595-596. doi: 10.7326/L20-1056.

3

Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.骨髓增生异常综合征及输血性铁过载患者铁螯合治疗指南。

Leuk Res. 2007 Dec;31 Suppl 3:S10-5. doi: 10.1016/S0145-2126(07)70461-7.

4

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).地拉罗司用于依赖输血的骨髓增生异常综合征患者：安全性、疗效及其他（GIMEMA MDS0306试验）

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

5

Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.使用铁螯合疗法改善骨髓增生异常综合征和铁过载患者的临床结局。

Leuk Res. 2007 Dec;31 Suppl 3:S7-9. doi: 10.1016/S0145-2126(07)70460-5.

6

Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.低危骨髓增生异常综合征患者接受铁螯合治疗与未接受螯合治疗的生存结局：观察性研究的综述与汇总分析

Leuk Res. 2017 Jun;57:104-108. doi: 10.1016/j.leukres.2017.03.007. Epub 2017 Mar 18.

7

Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?近期随机临床试验结果是否影响接受铁螯合治疗的骨髓增生异常综合征患者？

Hematol Oncol Clin North Am. 2020 Apr;34(2):465-473. doi: 10.1016/j.hoc.2019.10.006. Epub 2020 Jan 21.

8

Iron chelation therapy in myelodysplastic syndrome - Cui bono?骨髓增生异常综合征中的铁螯合疗法——谁将受益？

Leukemia. 2009 Aug;23(8):1373. doi: 10.1038/leu.2009.39.

9

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.充分的铁螯合治疗至少 6 个月可改善输血依赖型低危骨髓增生异常综合征患者的生存。

Leuk Res. 2014 May;38(5):557-63. doi: 10.1016/j.leukres.2014.02.003. Epub 2014 Feb 14.

10

Iron chelation therapy in MDS: does it improve survival?骨髓增生异常综合征中的铁螯合疗法：能否提高生存率？

Leuk Res. 2010 Jul;34(7):852-3. doi: 10.1016/j.leukres.2010.03.005. Epub 2010 Mar 25.

引用本文的文献

1

Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients.骨髓增生异常综合征患者铁螯合治疗的预后因素及临床考量

J Blood Med. 2021 Dec 3;12:1019-1030. doi: 10.2147/JBM.S287876. eCollection 2021.